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Abstract
The possible increase of suicidal ideation with some antidepressants is still a matter of debate. We
are reporting two cases of suicidal attempt that occurred concomitantly with the use of
Duloxetine. To our knowledge there is no prior publication about a possible Duloxetine related
increase in the risk of suicidality.
Background
An increase in suicidal ideation with antidepressants is
still a matter of debate [1-11]. The advent of SSRI antide-
pressants appears to have been accompanied with signifi-
cant decrease in suicide rates in most countries with
traditionally high baseline suicide rates [12,13]. More
recent larger clinical studies, in both adults and children
have confirmed the protective effects of antidepressants
against suicidality. The increased use of antidepressants
has reduced depressive morbidity and suicidal morality.
The significant relation between increasing antidepressant
utilization and decreasing national suicide rates does not
automatically suggest a causal association, but consider-
ing the strong (and causal) relationship between
untreated major mood disorder and suicidal behavior
most pharmaco-epidemiological studies strongly suggest
that more widespread and effective treatment of mood
disorders is a significant, although not the only factor in
decreasing suicide mortality at the level of the general
population[14].
Many of the suicide attempters with depression have been
thought to have "mixed" depressions with a 4.4 odds
compared to non-mixed depressions [15]. Of the symp-
toms of mixed depression, there is a significant associa-
tion between suicidal ideation, psychomotor activation
and racing thoughts which bears support to the hypothe-
sis that agitation is a suicide risk factor in patients with
depression [12]. The issue remains whether the "activa-
tion"/"agitation" seen with the use of antidepressants is
the direct results of their use and if this is the main factor
in the observed association between their use and the pos-
sible increase in suicidality in some reports[15,16].
Case reports
CASE I
A thirty year old married female was transferred to
SGUMC (Saint. George University Medical Center/Beirut)
for psychiatric evaluation and treatment after she had
attempted suicide by ingesting 250 ml of a detergent con-
taining a fatal substance (HCL) which had caused a severe
pyloric stenosis. History revealed an onset of major
depressive disorder for which she had been put on
Duloxetine 60 mg in addition to the Alprazolam she was
already on. Five days after the initiation of Duloxetine, she
felt an exacerbation of her depressive symptomatology
with an emergence of new symptoms of irritability and
agressivity. These symptoms worsened in severity and two
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the context of extreme irritability. She had no history of
previous suicidal attempts.
CASE II
A forty seven year old married female was admitted to
SGUMC for management of depression following a sui-
cide attempt (5 weeks post an overdose of Alprazolam).
She had a three year history of depression and generalized
anxiety disorder with multiple somatic complaints and
had been on Duloxetine 60 mg with Alprazolam 2 mg HS
for two months during which she reported improvement
in her mood as well as her somatic symptoms except for
lower limbs pain. Duloxetine had been then increased to
120 mg daily. About five days after this increase the
patient started feeling more pain with a new onset of irri-
tability. The depressive symptoms and irritability kept on
escalating and on the third week after the increase of
Duloxetine, the patient attempted suicide with an over-
dose of Alprazolam (22 mgs) without any plan. The
patient reported having a previous suicidal attempt at the
age of fifteen years.
Discussion
In both cases there is an emergence of suicidality in appar-
ently nonsuicidal patients after starting or increasing
Duloxetine. The duration after which suicidality emerged
is similar to what has been reported in the literature i.e. 1–
9 days [1-3]. In addition the symptoms that preceded the
suicidal attempts readdress the issue of antidepressant
induced suicidality occurring in the context of agitation,
irritability and impulsivity [3,4,9,10]. Antidepressant
monotherapy in patients with bipolar disorder and the
bipolar spectrum could worsen the preexisting mixed state
of depression or generate mixed conditions de novo,
resulting in treatment resistance, destabilization of the
mood disorder, worsening of the depression and, possibly
suicidal behavior in some patients [12,16]. The recogni-
tion of the important role of pseudo-unipolar mixed
states of depression in suicidal behavior has clear implica-
tions for suicide prevention. However, the rare occurrence
of suicidality on antidepressants should not obscure the
fact that the advent of the new antidepressants is associ-
ated with worldwide decline in suicide rates [13].
Conclusion
Observations do not necessarily implicate antidepressants
as being causative, but the possible emergence of suicidal-
ity could be mediated through what is referred to as the
"activation syndrome" possibly in patients with poten-
tially a bipolar spectrum. Clinical wisdom would suggest
that, faced with depressed patients, one must exercise
extreme caution in the first 4 weeks after prescribing anti-
depressants especially if unprotected by mood stabilizing
agents and/or atypical antipsyhotics [16].
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